The discovery of EGFR tyrosine kinase inhibitor (EGFR‐TKI) is an important milestone in the development of tumor‐targeted therapy in NSCLC and greatly improves the outcomes of NSCLC patients. Here, EGFR is linked to non-small cell lung carcinoma.